|
|
|
||||
| Home Help Feedback Subscriptions Archive Search | |||||
The fully linked HTML version of this article has now been published.
Transferrin receptor 2 (TfR2) possesses a YQRV motif similar to the YTRF motif of transferrin receptor 1 (TfR1) responsible for the internalization and secretion through the endosomal pathway. Raft biochemical dissection showed that TfR2 is a component of the low-density Triton-insoluble (LDTI) plasma membrane domain, able to co-immunoprecipitate with caveolin-1 and CD81, two structural raft proteins. In addition, subcellular fractionation experiments showed that TfR1, which spontaneously undergoes endocytosis and recycling, largely distributed to intracellular organelles, whereas TfR2 was mainly associated with the plasma membrane. Given the TfR2 localization in lipid rafts, we tested its capability to activate cell signalling. Interaction with an anti-TfR2 antibody or with human or bovine holotransferrin showed that it activated ERK1/ERK2 and p38 MAP kinases. Integrity of lipid rafts was required for MAPK activation. Co-localization of TfR2 with CD81, a raft tetraspanin exported through exosomes, prompted us to investigate exosomes released by HepG2 and K562 cells into culture medium. TfR2, CD81 and to a lesser extent caveolin-1, were found to be part of the exosomal budding vesicles. In conclusion, the present study indicates that TfR2 localizes in LDTI microdomains, where it promotes cell signalling, and is exported out of the cells through the exosome pathway, where it acts as an intercellular messenger.
This article has been cited by other articles:
JCS ePress
online publication date 17 Oct 2006
doi: 10.1242/jcs.03228
This Article ![]()
![]()
Full Text (PDF)
![]()
All Versions of this Article:
jcs.03228v1
119/21/4486
most recent![]()
Alert me when this article is cited
![]()
Alert me if a correction is posted
![]()
Services ![]()
![]()
Email this article to a friend
![]()
Similar articles in this journal
![]()
Similar articles in PubMed
![]()
Alert me to new issues of the journal
![]()
Download to citation manager
![]()
![]()
Citing Articles ![]()
![]()
Citing Articles via HighWire
![]()
Citing Articles via Google Scholar
![]()
Google Scholar ![]()
![]()
Articles by Calzolari, A.
![]()
Articles by Testa, U.
![]()
Search for Related Content
![]()
PubMed ![]()
![]()
PubMed Citation
![]()
Articles by Calzolari, A.
![]()
Articles by Testa, U.
Research Article
TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway
* Author for correspondence (e-mail: u.testa{at}iss.it)
![]()
![]()

![]()
![]()
![]()
D. L. Sprague, B. D. Elzey, S. A. Crist, T. J. Waldschmidt, R. J. Jensen, and T. L. Ratliff
Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles
Blood,
May 15, 2008;
111(10):
5028 - 5036.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
D. F. Wallace, L. Summerville, E. M. Crampton, and V. N. Subramaniam
Defective trafficking and localization of mutated transferrin receptor 2: implications for type 3 hereditary hemochromatosis
Am J Physiol Cell Physiol,
February 1, 2008;
294(2):
C383 - C390.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
R. Valenti, V. Huber, M. Iero, P. Filipazzi, G. Parmiani, and L. Rivoltini
Tumor-Released Microvesicles as Vehicles of Immunosuppression
Cancer Res.,
April 1, 2007;
67(7):
2912 - 2915.
[Abstract]
[Full Text]
[PDF]
![]()
© The Company of Biologists Ltd 2006